Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-742X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel ; volume:46 ; number:4 ; day:3 ; month:8 ; year:2018 ; pages:488-495 ; date:11.2018
Journal of thrombosis and thrombolysis ; 46, Heft 4 (3.8.2018), 488-495, 11.2018
- Urheber
-
Kitazono, Takanari
- Beteiligte Personen und Organisationen
-
Ikeda, Yasuo
Nishikawa, Masakatsu
Yoshiba, Satoshi
Abe, Kenji
Ogawa, Akira
SpringerLink (Online service)
- DOI
-
10.1007/s11239-018-1714-2
- URN
-
urn:nbn:de:101:1-2018111320025308482207
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kitazono, Takanari
- Ikeda, Yasuo
- Nishikawa, Masakatsu
- Yoshiba, Satoshi
- Abe, Kenji
- Ogawa, Akira
- SpringerLink (Online service)
Ähnliche Objekte (12)
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel
Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention
Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis
Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis
![Cytochrome P450 : [with 55 tables]](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Cytochrome P450 : [with 55 tables]
Problems with Antiplatelet Therapy in Children with Cyanotic Heart Disease
Initial 3-Weeks’ Apixaban Versus Dual-Antiplatelet Therapy (Clopidogrel and Aspirin) Followed by Clopidogrel Alone in High-Risk Patients with Acute Non-Disabling Cerebrovascular Events (ADANCE): Study Protocol for a Randomized Controlled Trial
Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study
Prevalence of antiplatelet therapy in patients with diabetes
Antiplatelet therapy with CABG: chaos in the Netherlands
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel
Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention
Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis
Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis
Cytochrome P450 : [with 55 tables]
Problems with Antiplatelet Therapy in Children with Cyanotic Heart Disease
Initial 3-Weeks’ Apixaban Versus Dual-Antiplatelet Therapy (Clopidogrel and Aspirin) Followed by Clopidogrel Alone in High-Risk Patients with Acute Non-Disabling Cerebrovascular Events (ADANCE): Study Protocol for a Randomized Controlled Trial
Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study
Prevalence of antiplatelet therapy in patients with diabetes
Antiplatelet therapy with CABG: chaos in the Netherlands
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel
Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention
Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis
Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis
Cytochrome P450 : [with 55 tables]
Problems with Antiplatelet Therapy in Children with Cyanotic Heart Disease
Initial 3-Weeks’ Apixaban Versus Dual-Antiplatelet Therapy (Clopidogrel and Aspirin) Followed by Clopidogrel Alone in High-Risk Patients with Acute Non-Disabling Cerebrovascular Events (ADANCE): Study Protocol for a Randomized Controlled Trial
Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study
Prevalence of antiplatelet therapy in patients with diabetes